Krystal Biotech 12-Month Price Target Raised to $409.38
The revised target implies 28% upside.
Related stories
三六零 Says Q3 Revenue Fell 3.9% Year Over Year
M impact | EQUITY | Oct 29, 2026, 09:38 AM UTC
Linde Q3 Revenue Rises 9% on Higher Pricing and Volumes
M impact | EQUITY | Oct 29, 2026, 09:38 AM UTC
MGRC Reports Fiscal Q3 Profit and EPS
MGRC reported fiscal 2026 third-quarter profit attributable to shareholders, up 2.84% year over year, and basic EPS.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
ROG Reports Fiscal Q3 Profit Growth of 161.3%
ROG reported fiscal 2026 third-quarter profit attributable to shareholders up 161.3% year over year, with basic EPS also reported.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
PBI Reports Fiscal Q3 Profit and EPS
Profit attributable to shareholders rose 36.94% year over year; basic EPS was also reported.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
Company Reports Fiscal Q3 Attributable Loss
The company reported attributable profit of -7.29亿美元 for fiscal Q3 2026, down 371% year over year.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC